News Agency
The Times

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

  • Written by PR Newswire
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
  • Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026
  • Appoints US-based Chief Commercial Officer, Andrew Udell
  • Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media.

SYDNEY, Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the first...

Read more: Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

How Australian Businesses Can Prepare Their Websites for AI-Powered Search Results

Search is changing rapidly. While traditional search engines remain a major source of website traffic, customers are increasingly using AI-powered platforms to discover information, compare businesses and make purchasing decisions. For Australian businesses, this shift creates a new challenge: ensuring... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion